Table 1.
Descriptive parameters of the total study population
| Study population | Responsive group | Resistant group | ||
|---|---|---|---|---|
| Demographic factors | Patients | 69 | 58 | 11 |
| Women | 52 | 46 | 6 | |
| Men | 17 | 12 | 5 | |
| Endocrinological factors |
Baseline PRL [median (interquartile range)] |
116.98 μg/l (294,46) | 105.66 μg/l (284,17) | 259.77 μg/l (842,24) |
|
PRL after 3 months: Reduction [mean (standard deviation)] |
83.3% (20.56) | 85.9% [11, 15] | 67.5% (31,75) | |
| PRL after 3 months: Normalization | 62.0% | 70.5% | 0.0% | |
|
PRL after 4 months: Reduction [mean (standard deviation)] |
82.7% (22,85) | 87.4% (18,95) | 63.8% (30,32) | |
| PRL after 4 months: Normalization | 79.0% | 87.5% | 0.0% | |
| MRI factors |
Tumour volume [median (interquartile range)] |
0.18 cm3 (1,32) | 0.13 cm3 (0,88) | 3.34 cm3 [5, 7] |
| Microadenoma | 54.4% | 59.6% | 27.3% | |
| Macroadenoma | 45.6% | 40.4% | 72.7% | |
|
Contrast capitation [mean (standard deviation)] |
1.93 (0,81) | 1.88 (0,70) | 2.40 (1,43) | |
| Presence of cystic/hemorraghic/necrotic component | 26.7% | 20.7% | 71.4% |
PRL: Prolactin; Contrast capitation: the ratio of the density factor on T1 after contrast to the value on T1 without contrast